石藥集團：與 CORBUS PHARMACEUTICALS 就 SYS6002 訂立獨家授權協議

智通財經
2023.02.12 23:18
石藥集團港交所公告稱，已與 Corbus Pharmaceuticals 就本集團重組人源化抗 Nectin-4 抗體藥物偶聯物 SYS6002 在美國、歐盟國家、英國、加拿大、澳大利亞、冰島、列支敦士登、挪威及瑞士的開發及商業化訂立獨家授權協議。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.